FDA clears Dexcom Smart Basal, a CGM-based basal insulin dose calculator for type 2 diabetes

On November 18, 2025, the FDA cleared Dexcom Smart Basal through the 510(k) pathway under number K252818, finding it substantially equivalent to a device already on the market.[1] Dexcom received the decision about two and a half months after filing: the agency's record shows the submission arrived on September 4, 2025.[1] Dexcom announced the clearance a day later, on November 19, 2025, and described Smart Basal as a basal insulin dosing optimizer built around its CGM for adults with type 2 diabetes.[2]

What the FDA cleared

Smart Basal is software, not a new sensor. FDA's indications for use describe it as an insulin dose calculator "intended for the management of type 2 diabetes in persons aged 18 years and older requiring long-acting insulin," and they state it is not for people on fast-acting insulin.[3] It calculates a dose of basal (long-acting) insulin from two inputs: the doses the user logs, and readings from an integrated continuous glucose monitor (iCGM).[3]

The clearance carries two conditions that matter to readers. Smart Basal requires a prescription, and a healthcare provider has to configure it before use.[3] FDA classified it as a Class II "insulin therapy adjustment device" under product code QRX.[3]

Dexcom's release narrows the use further. It says the software is designed for adults with type 2 diabetes on glargine U-100, a long-acting insulin, and that it will use data from the Dexcom G7 15 Day sensor.[2]

How Dexcom says it works

According to Dexcom, a healthcare provider sets the starting basal dose.[2] From there, the user gets daily dose recommendations and reminders in the Dexcom G7 15 Day app, based on all of their CGM readings rather than a single fasting fingerstick value.[2] If low glucose events happen, the software lowers its recommendation by an amount the provider chose.[2] Once glucose stays in the target range the provider set, the user receives a final dose and the program ends.[2]

The 510(k) summary describes how the system is built. The system has three pieces: a cloud-based dose calculator, a module inside a compatible Dexcom CGM app, and a web tool for providers.[3] Dexcom said providers will prescribe and set it up through Dexcom Clarity.[2]

The evidence FDA reviewed

The predicate device, the one FDA compared Smart Basal against, was Welldoc's BlueStar CGM insulin dose calculator (K222888), which calculates bolus doses for people who use fast-acting insulin.[3] Dexcom's clinical study enrolled people with type 2 diabetes who used a CGM and took only basal insulin.[3] The summary reports that average time in range (the share of time between 70 and 180 mg/dL) after titration was not worse than before it, that the improvement was statistically significant, and that there were no device-related adverse events.[3] The summary does not give the size of the study or the actual time-in-range numbers, so we can't report them.

What this means for you

Dexcom said Smart Basal would be added to the Dexcom G7 15 Day experience shortly after that sensor launched in the United States, and that work was underway to offer it outside the US later.[2] It is prescription software: a provider prescribes it, sets the starting dose and chooses how the recommendations adjust.[2][3] Questions about starting or changing insulin: talk to your care team or pharmacist.